DNA:NYE-Ginkgo Bioworks Holdings (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.8601

Change

0.00 (0.00)%

Market Cap

USD 2.17B

Volume

0.07B

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

N/A

USD 567.03B
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 3.15B
HTD John Hancock Tax Advantaged Di..

N/A

USD 2.41B
RCUS Arcus Biosciences Inc

N/A

USD 1.41B
NUVB Nuvation Bio Inc

N/A

USD 0.64B
ADCT ADC Therapeutics SA

N/A

USD 0.36B
PGP PIMCO Global StocksPLUS & Inco..

N/A

USD 0.32B
CYBN Cybin Inc

N/A

USD 0.29B
ATNM Actinium Pharmaceuticals Inc

N/A

USD 0.27B
LCTX Lineage Cell Therapeutics Inc

N/A

USD 0.20B

ETFs Containing DNA

SPAK 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -49.11% 20% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.11% 20% F 1% F
Trailing 12 Months  
Capital Gain -29.50% 30% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.50% 29% F 8% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -27.89% 23% F 2% F
Dividend Return -27.89% 23% F 2% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.55% 74% C 38% F
Risk Adjusted Return -94.38% 9% A- 2% F
Market Capitalization 2.17B 91% A- 65% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector